Active surveillance and its role in the management of lower-risk forms of prostate cancer, and related issues like MRI scanning, were clearly key topics of attention at the annual meeting of the European Association of Urology in Barcelona over the weekend.
Rather that try to re-invent the wheel, we would refer our readers to a number of presentations on the UroToday web site that reported on a range of presentations listed below:
- Dr R. van den Bergh, of University Medical Center Utrecht, Nieuwegein, the Netherlands, gave an interesting presentation on “The urologist’s perspective on active surveillance” (as reported by Dr. Hanan Goldberg for UroToday).
- Dr. J. Barentz, of Radboudumc, Nijmegen, The Netherlands, reported on “The role of (fast) bi-parametric MRI versus multi-parametric MRI and TRUS-biopsy for detecting clinically significant prostate cancer in biopsy naïve men with elevated PSA” (as reproted by Zachary Klaassen for UroToday).
- Dr. Alberto Briganti provided an overview and discussion following the presentation by Dr. Barentz (again as reported by Dr. Zachary Klaassen for UroToday)
- Dr. Olivier Rouvière, of the Department of Urinary and Vascular Imaging, Centre Hospitalier Universitaire de Lyon, Lyon, France, reported on “The imaging specialist’s perspective on MRI for prostate cancer” (as reported by Hanan Goldberg for UroToday), and which specifically included the roles of MRI in the initial diagnosis of prostate cancer and its use in monitoring men on AS.
- John Dowling, the Secretary of Europe Uomo gave a presentation entitled “The patient’s perspective on prostate cancer” (again as reported by Hanan Goldberg for UroToday) that includes data on the rates at which AS is being offered to patients considered appropriate for this form of initial management in different European nations.
You do need to register on the UroToday web site to be able to read this material, but it is a free service to patients.
Filed under: Uncategorized | Tagged: active, annual meeting, EAU, surveillance |
THE "NEW" PROSTATE CANCER INFOLINK 
Leave a Reply